ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India
CompanyDeals

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India

Wellington Zhaotai Therapies Limited (WZTL), a holding platform under China's Zhaotai Medical, officially signed a CAR‑T cell therapy technology sublicensing agreement with New Zealand's BioOra in Auckland, with a total…

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial
CompanyDrug

Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial

Biokin's BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers
CompanyDrug

Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1
CompanyDrug

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1

Biokin Receives NMPA Approval for CD33 ADC in AML Trial
CompanyDrug

Biokin Receives NMPA Approval for CD33 ADC in AML Trial

Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518
CompanyDrug

Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518

Grand Pharma's GPN02006 Shows Promising HCC Diagnostic Results in Trial
CompanyDrug

Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies
CompanyDrug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

Show More